Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 2/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | LOX | P28300 | 1/20 | 0.37 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.37 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.37 |
| ▸ | IKBKB | O14920 | 1/20 | 0.36 |
| ▸ | FDPS | P14324 | 1/20 | 0.36 |
| ▸ | KMO | O15229 | 1/20 | 0.36 |
| ▸ | LNPEP | Q9UIQ6 | 5/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31678696 | 1.00 | ROCK1 (0.40) | ROCK1OPRK1KCNH2OPRM1RECQL | |
| SCHEMBL17396860 | 0.93 | LOX (0.40) | ROCK1OPRK1KCNH2OPRM1LOX | |
| SCHEMBL190777 | 0.91 | LOX (0.45) | LOXLOXL2FDPSKMOLNPEP | |
| SCHEMBL2596263 | 0.88 | PDE2A (0.41) | LRRK2 | |
| SCHEMBL30187757 | 0.88 | ROCK1 (0.55) | ROCK1IKBKB | |
| SCHEMBL13806585 | 0.88 | ROCK1 (0.55) | ROCK1IKBKB | |
| SCHEMBL12234578 | 0.85 | HRH3 (0.47) | ROCK1LNPEPLRRK2 | |
| SCHEMBL23975906 | 0.84 | KMO (0.40) | ROCK1OPRK1KCNH2OPRM1RECQL | |
| SCHEMBL31678745 | 0.84 | KMO (0.40) | ROCK1OPRK1KCNH2OPRM1RECQL | |
| SCHEMBL30694895 | 0.84 | SLC6A4 (0.57) | ROCK1KCNH2SLC6A4SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250270190-A1 | KIT INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2025-08-28 | — | — | US | disclosed |
| EP-2948458-B1 | BTK INHIBITORS | MERCK SHARP & DOHME (US) | 2019-05-01 | — | — | EP | disclosed |
| EP-2734529-B1 | BTK INHIBITORS | MERCK SHARP & DOHME (US) | 2018-09-05 | — | — | EP | disclosed |
| US-9718828-B2 | BTK Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-08-01 | — | — | US | disclosed |
| US-20170008899-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-01-12 | — | — | US | disclosed |
| US-9481682-B2 | Substituted benzamides and substituted pyridinecarboxamides as Btk inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-11-01 | — | — | US | disclosed |
| US-20150353570-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-12-10 | — | — | US | disclosed |
| EP-2948458-A1 | BTK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2015-12-02 | — | — | EP | disclosed |
| US-20140221333-A1 | BTK INHIBITORS | MERCK SHARP & DOHME B.V. (NL) | 2014-08-07 | — | — | US | disclosed |
| WO-2014113932-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-07-31 | — | — | WO | disclosed |
| WO-2014114185-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-07-31 | — | — | WO | disclosed |
| US-20140206681-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. | 2014-07-24 | — | — | US | disclosed |
| EP-2734529-A1 | BTK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2014-05-28 | — | — | EP | disclosed |
| WO-2013010380-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170008899-A1 | BTK INHIBITORS | BTK, SYK, ABL1 | ROCK1 623/4885OPRK1 4552/4885KCNH2 2861/4885 |
| US-20250270190-A1 | KIT INHIBITORS | KIT, ABL1, APC | ROCK1 208/4885OPRK1 2303/4885KCNH2 1068/4885 |
| US-20140206681-A1 | BTK INHIBITORS | BTK, SYK, LYN | ROCK1 240/4885OPRK1 4545/4885KCNH2 2330/4885 |
| US-20150353570-A1 | BTK INHIBITORS | BTK, SYK, LYN | ROCK1 240/4885OPRK1 4545/4885KCNH2 2330/4885 |
| US-20140221333-A1 | BTK INHIBITORS | BTK, SYK, ABL1 | ROCK1 631/4885OPRK1 4559/4885KCNH2 2735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.